Form 4 for ORKA Oruka Therapeutics, Inc.
Accepted 2021-11-23 00:00:00 ET · period of report 2021-11-22 · accession 0001209191-21-066497 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-11-23 | 2021-11-22 | ORKA | Ozeroff Christopher David | SVP, GC | P - Purchase | $2.26 | +50.0K | 51.0K | +5,155% | +$113.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-22 | P | A | 50,000 | $2.26 | 50,970 | D | — | — | (F1) The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $2.21 to $2.329. Upon request of the SEC staff, ARCA biopharma, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares purchased at each separate price. |